• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

OpGen

edit

OpGen is commercializing a novel single molecule DNA analysis technology, “Optical Mapping”, for rapid identification and analysis of microorganisms. The system can be used to obtain detailed genetic information with no requirement for prior sequence data, PCR, cloning, or probes. Applications of the new commercial systems include clinical microbial analysis, forensic microbiology and the development of novel molecular diagnostic products.

Milestones

edit

• 
  OpGen added Evan Jones as Interim CEO. (12/1/09)
  Posted 12/11/09 at 5:30pm
• 
  OpGen added Trevor D'Souza as Observer.
  Posted 12/11/09 at 5:30pm
• 
  OpGen added Brian Atwood as Director.
  Posted 12/11/09 at 5:30pm
• 
  OpGen added Bijan Salehizadeh, MD as Director.
  Posted 12/11/09 at 5:30pm
• 
  OpGen added Corey Mulloy as Director.
  Posted 12/11/09 at 5:30pm
• 
  OpGen added Ronald Lennox as Chairman.
  Posted 12/11/09 at 5:30pm
• 
  OpGen received $17M in Series B funding. (9/28/10)
  Posted 9/27/10 at 9:41pm via opgen.com
• 
  OpGen received $23.6M in Series A funding. (9/12/07)
  Posted 3/12/10 at 3:50am via opgen.com
• 
  OpGen received $2M in Debt funding. (12/11/09)
  Posted 12/11/09 at 5:30pm via sec.gov
• 
  OpGen — OpGen Topping Off Series B Round For DNA-Analysis Instrument Sales (2/9/11)
  Posted 2/8/11 at 7:57pm via dowjones.com

Videos

Screenshots

edit

Above: OpGen
Uploaded: 3/12/10

Sources

1. OpGen Announces $23.6 Million Series A Financing (opgen.com) [edit]
2. SEC D (sec.gov) [edit]
3. OpGen Completes $17 Million Series B Financing (opgen.com) [edit]
4. OpGen Topping Off Series B Round For DNA-Analysis Instrument Sales (fis.dowjones.com) [edit]